Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more

3060 Pegasus Park Drive, Dallas, TX, 75247, United States

Biotechnology
Healthcare

Market Cap

335M

52 Wk Range

$4.90 - $35.62

Previous Close

$26.74

Open

$26.86

Volume

152,623

Day Range

$26.86 - $28.96

Enterprise Value

239.4M

Cash

93.41M

Avg Qtr Burn

-14.0M

Insider Ownership

3.97%

Institutional Own.

-

Qtr Updated

09/30/25